Trial Profile
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms ACTT-3
- 29 Nov 2022 Results post hoc of analysis compared recovery and mortality between these comparable sequential cohorts of patients who received remdesivir plus SOC, adjusting for baseline characteristics with propensity score weighting published in the Annals of Internal Medicine
- 04 Feb 2021 Status changed from active, no longer recruiting to completed.
- 11 Nov 2020 Planned End Date changed from 1 Nov 2023 to 30 Dec 2020.